The influence of personality on health related quality of life (QoL) and physical functioning in the setting of allogeneic hematopoietic SCT (alloHSCT) is unknown. We conducted a joint evaluation within two independent cohorts of alloHSCT recipients to investigate the impact of personality on reported QoL and physical functioning. Two-hundred-eight patients (median age 44 years, range 18-72) of cohort 1 and 93 patients (median age 55 years, range 19-79) of cohort 2 after alloHSCT were evaluated. Personality was assessed using the 24-adjective measure (AM), which measures the Big-Five personality domains and the Life Orientation Test-Revised (LOT-R), measuring optimism and pessimism. QoL was measured using the Functional Assessment of Cancer Therapy with bone marrow transplantation subscale (FACT-BMT), Short Form 36 (SF-36), the human activity profile (HAP), as well as the NIH criteria-based cGVHD activity assessment form and the Lee cGVHD symptom scale. Neuroticism was significantly associated with worse function measured by the HAP and FACT-BMT. Optimism significantly improved QoL captured by the FACT-BMT. Pessimism significantly impaired physical function captured by the HAP and SF-36. Extraversion was significantly associated with reduced depression and lower severity of cGVHD symptoms reported by the patient and the physician. The results suggest that personality traits and pre-treatment QoL assessments should be measured in clinical trials to facilitate the interpretation of QoL data.
INTRODUCTION
Quality of life (QoL) and physical functioning are the major concerns of patients receiving allogeneic hematopoietic SCT (alloHSCT) as disease and associated treatment can cause significant long-term morbidity. [1] [2] [3] Therefore, QoL and selfreported functional assessments are often incorporated into clinical trials and serve as important secondary end points. Physical functioning may be more affected by cancer treatment than some other domains. 4 Chronic GVHD (cGVHD) is a common complication after alloHSCT that shares many clinical features with autoimmune diseases. In recognition of the importance of measuring QoL in patients with cGVHD, the NIH Consensus Conference on cGVHD recommended several instruments to be used as part of a patient self-reported battery within clinical trials. [5] [6] [7] One of the criticisms of using QoL as an end point in treatment trials is that its multidimensional nature impairs linear conclusions with regard to disease severity and response to treatment. 8 Other factors besides current physical status, such as inherent personality and extraneous experiences, affect how patients report their QoL, a fact well known empirically but rarely studied in cancer patients. [9] [10] [11] Some work has been reported in patients with breast cancer or after solid organ transplantation, but little is known in the setting of alloHSCT. [12] [13] [14] [15] [16] Personality is considered to change little after age 30, and personality traits might be considered as basic invariant characteristics like sex, race and education, which affect a person's view of the world. 17 The Big-Five Model is the predominant model of personality in psychology, 18 with the 240-item Revised NEO Personality Inventory measuring the five factors (personality traits: neuroticism, extraversion, openness to experience, agreeableness, conscientiousness) being the gold standard for assessment. 19 However, this instrument is too lengthy for many research applications. Therefore, several shorter instruments were developed and validated, including the 24-adjective measure (24-AM). 20 The goal of the current study was to measure the impact of personality on the manner in which patients with cGVHD after alloHSCT report their QoL, physical functioning and disease 1 symptoms. The primary analysis was performed within a GermanAustrian cohort, and validated with an independent American cohort.
PATIENTS AND METHODS Patients
German-Austrian cohort. Data were collected as part of a prospective multicenter study of alloHSCT survivors. 7, 21 Two-hundred-eight patients who received an alloHSCT for hematologic malignancies (n ¼ 206), aplastic anemia (n ¼ 1) or paroxysmal nocturnal hemoglobinuria (n ¼ 1) with a median age of 44 (range: 18-72) years were included into the trial at six German and one Austrian institutions. Patients were enrolled during regular visits at the transplant center after obtaining informed consent between 3 months and 1 year after alloHSCT, or in the presence of active cGVHD requiring immunosuppressive treatment after day 100 without time limit (inclusion criteria). Exclusion criteria were life expectancy o3 months, inability to understand and fill out the forms without assistance, or relapse of the underlying malignancy. While 136 patients had cGVHD at the time of inclusion into the trial, 72 patients were recruited in the absence of cGVHD. Patients without cGVHD were included in order to control for the effect of cGVHD. The study was reviewed and approved by an Institutional Review Board at each center.
American cohort. Patients were enrolled in an observational longitudinal study of people with cGVHD treated at the Fred Hutchinson Cancer Research Center. Ninety-three patients who received an alloHSCT for hematologic malignancies (n ¼ 89) or non-malignant conditions (n ¼ 4) were included in the trial. The median age was 55 years (range: 19-79 years). While 78 patients had cGVHD at the time of inclusion, 3 patients had late acute GVHD and 12 patients were included in the absence of GVHD.
Comparison of the German-Austrian and American cohorts. Although the two cohorts were relatively similar, some relevant characteristics differed significantly between the German-Austrian and the American patients. The German-Austrian cohort included patients with and without cGVHD, while the American cohort included mostly patients with cGVHD (n ¼ 78). Patients in the German-Austrian cohort were more likely to have severe cGVHD. Patients with late acute GVHD present in the American sample (n ¼ 3) were not included in the German-Austrian cohort. American patients tested were older (median age 11 years older) than the GermanAustrian patients and had higher levels of agreeableness (Po0.001). The German-Austrian patients reported higher levels of neuroticism. Detailed patient characteristics are displayed in Table 1 .
Methods
Data collection instruments. German-Austrian cohort: Patients completed the German versions of the L-cGVHD-SC, 6 Functional Assessment of Cancer Therapy with bone marrow transplantation subscale (FACT-BMT), 22 human activity profile (HAP), 4,23 Short Form 36 (SF-36), 24 the 24-AM (measuring personality), Life Orientation TestRevised (LOT-R, covering optimism and pessimism), 20, 25, 26 and the Hospital Anxiety and Depression Scale. 27, 28 The German and English versions of the 24-AM are available on www.gvhd.eu. Follow-up surveys included in the analysis were conducted at 1, 2, 3 and 5 months after the baseline survey. The 24-AM and LOT-R were captured twice, at the time of enrollment and 2 months later, permitting a test-retest analysis. All other evaluations were performed at the time of inclusion. All patients were evaluated by clinicians according to the NIH criteria-based diagnosis and scoring form, the cGVHD activity assessment form and the NIH-Symptom-Scale as a measure of cGVHD symptoms, 21 and overall severity was collected on a 10-point scale. 7 Disease status, comorbidities and medication were documented by the care-giving physician. 21 American cohort: All patients were evaluated according to the diagnosis and scoring form, the NIH criteria-based activity assessment form (patient and physician), the L-cGVHD-SC, the FACT-BMT, the SF-36 and the HAP. Sociodemographic data were collected from patients or the medical records. Clinical data were abstracted from medical records. Follow-up visits were performed at 3 and 6 months after enrollment. In contrast to the German-Austrian Cohort, the 24-AM and LOT-R were collected from participants only once and the Hospital Anxiety and Depression Scale was not collected.
Measures. For assessing personality factors, we used the 24-AM, which is a brief measure of the Big-Five domains. 20 The 24-AM measures the personality domains neuroticism, extraversion, openness to experience, agreeableness and conscientiousness.
The LOT-R measures respondents' dispositional level of optimism.
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LOT-R was chosen because it is the most common measure of optimism. The measure consists of six items, three of which are positively valenced (representing optimism items) and three are negatively valenced (representing pessimism items). Participants indicated the extent to which they agree to each item on a 5-point Likert-type scale, with anchors ranging from I agree a lot (1) to I disagree a lot (5). Psychometric properties (Cronbach's alpha as a measure of reliability and test-retest correlation as a measure of stability) of both measures are provided in Table 2 .
Biostatistical methods. Instruments were scored according to the recommendations of the developers. For all instruments except the L-cGVHD-SC, higher scores indicate better functioning. For the L-cGVHD-SC, higher scores indicate higher symptom burden. Data were analyzed with the Statistical Package for Social Sciences 15.0 (SPSS Inc., Chicago, IL, USA) and checked for normality and homogeneity of variance before analysis. Furthermore, all study variables were examined through various SPSS programs for accuracy of data entry, missing values, and fit of their distribution and the assumptions of multivariate analysis. Pair-wise linearity was checked using scatter plots and was found to be satisfactory. Multivariate analyses included hierarchical multiple regression analysis and path analysis. Path analysis is an extension of the regression model controlling interdependence between variables. The global-cGVHD status was included in all models to adjust for the effects of cGVHD on QOL and physical functioning. Age and sex did not show any effect on the evaluated end points and were not included into the final analysis. Path analyses were conducted with LISREL 8.5 (Scientific Software International, Inc., 29 Statistical significance for all analyses was established when the two-tailed P-value was less than Po0.01. Results with borderline significance (P ranging between 0.05 and 0.01) are reported separately.
RESULTS

Psychometric testing of the personality measures (24-AM and LOT-R)
The psychometric properties for the 24-AM and LOT-R are reported in Table 2 . Results indicate reasonable internal consistency if the brevity of the scales is taken into account, ranging from 0.55 (openness) to 0.82 (extraversion) for the GermanAustrian cohort and from 0.50 (openness) to 0.83 (extraversion) for the American cohort. Results are comparable across both cohorts with the exception of neuroticism, which is less reliably assessed in the American cohort. Stability estimates are comparable to findings from other short Big-Five questionnaires. 19 LOT-R reliabilities are comparable to the values reported in previous research, with the exception of pessimism in the American cohort.
Impact of personality on QoL assessments
The impact of personality on QoL assessments was estimated by means of path analysis in order to take the inter-correlations of the personality measures and the QoL assessments into account and to incorporate control variables (sex, age and cGVHD severity) in the analyses. The global-cGVHD status was included in all models because of its known association with QoL and physical functioning (see Table 3 ). Owing to space restrictions, only significant results are presented (Po0.01). In addition, results at borderline significance level (P ¼ 0.01-0.05) are reported if a significant impact was detected in the other cohort as well.
Impact of Big-Five dimensions
Results from the German-Austrian Cohort: Neuroticism explained the most variance in the Big-Five model, significantly predicting worse modified (P ¼ 0.031) HAP-scores, and worse FACT-BMT scores, including lower physical (P ¼ 0.027) and emotional (Po0.001) well-being, worse scores on the BMT subscale (P ¼ 0.001) and FACT total score (P ¼ 0.037). Neuroticism was also associated with a worse mental score of the L-cGVHD-SC (Po0.001) (higher scores of L-cGVHD-SC implicate higher symptom load) (Figure 1c) . Extraversion, openness to experience and conscientiousness had no detectable association with QoL assessments and the HAP. Agreeableness was moderately associated with better social wellbeing (P ¼ 0.027) on the FACT-BMT. Extraversion was associated with lower ratings of depression (Po0.001).
Results from the American Cohort: Neuroticism was associated with worse functioning as measured by the modified (P ¼ 0.001) HAPscore. On the FACT-BMT, neuroticism was associated with worse physical (Po0.001), social (P ¼ 0.011), emotional (Po0.001), functional (Po0.001) and BMT-subscale (Po0.001) well-being (Figure 1a) . Finally, neuroticism was associated with worse energy scores from the L-cGVHD-SC (P ¼ 0.01). Extraversion was associated with better modified HAP scores (P ¼ 0.017) and better scores of the BMT subscale (P ¼ 0.003), but worse mental scores of the L-cGVHD-SC (Po0.001), suggesting that higher symptom loads are reported by extraverted patients. Extraversion was also associated with better energy scores of the L-cGVHD-SC (P ¼ 0.01). Openness to experience impaired the physical (Po0.001), social (Po0.001) and functional (Po0.001) well-being assessed by the FACT-BMT. Conscientiousness had a positive impact on the mental health summary score (P ¼ 0.01) of the SF-36, and reduced the reported symptom load of the mental subscale of the L-cGVHD-SC (P ¼ 0.003). Agreeableness was associated with worse physical well-being (P ¼ 0.013) measured by the FACT-BMT, but with less symptom burden on the L-cGVHD-SC mental scale (Po0.001).
Impact of optimism and pessimism
Results from the German-Austrian cohort: Optimism was moderately associated with better scores of the social well-being scale Results from the American cohort: Optimism was moderately related to the emotional (P ¼ 0.002) well-being scale of the FACT-BMT and reduced the reported symptom load in the mental score of the L-cGVHD-SC (Po0.001) (Figure 1e ). Pessimism was associated with worse modified HAP score (Po0.001), worse physical health summary score (P ¼ 0.028) of the SF-36, worse mental score of the L-cGVHD-SC (P ¼ 0.02), worse functional well-being (Po0.001) and worse BMT-subscale scores (P ¼ 0.002) of the FACT-BMT (Figure 1b) .
Impact of personality on severity assessment of cGVHD We also hypothesized that patient personality influences the assessment of overall cGVHD severity as measured by a 10-point scale ranging from 0 (not at all severe) to 10 (most severe GVHD symptoms possible) rated by the physician as well as by the patient. Table 4 provides the zero-order correlations between physicians' and patients' severity assessment of cGVHD and personality. Results indicate significant correlations between severity assessment of cGVHD for both assessors and the patient personality trait extraversion, as well as anxiety and depression. Optimism is significantly related to patient's assessment only. In contrast, patients with higher levels in anxiety and depression rated their cGVHD as more severe and were also rated higher on severity of cGVHD by physicians. Patients and physicians reported similar overall cGVHD severity for both the German-Austrian and American cohorts (0.63 and 0.54, respectively, Po0.001). However, personality variables were not associated with the agreement between physicians' and patients' assessments of cGVHD severity.
DISCUSSION
QoL and physical functioning are frequently applied as important end points of clinical trials. 30 However, both are influenced by multiple cofactors besides the disease and treatment impairing the analysis of the direct relationship with the treatment. 8 For example, psychosocial characteristics, co-morbidities and side effects of the applied treatment may influence the patient experience and how they report this to others. Personality has been identified as a major factor predicting QoL in a variety of diseases including cancer and in recipients of solid organ transplantation. 9,10,13-15, 31 Siassi et al. 15 demonstrated a greater impact of personality on QoL after colorectal surgery for malignant diseases than the malignant disease itself. While correlation usually does not prove causation, personality is felt to be a stable patient characteristic, much like age and gender, which are not malleable or situation-dependent, and predates the cancer and alloHSCT experience.
The analysis within both cohorts revealed a significant impact of personality on QoL, with neuroticism having the most significant influence on reported QoL captured by the FACT and the mental score of the L-cGVHD-SC, reaching almost the level of impact of cGVHD severity itself as shown in Table 3 . This profound effect of neuroticism on reported QoL has been reported in a variety of malignant diseases, as well as after kidney transplantation. 9, 14, [31] [32] [33] In contrast, the personality trait extraversion has a more complex impact on reported QoL and varies with nationality. While the effect of extraversion was not detectable in the German-Austrian cohort, within the American cohort extraversion positively influenced reported QoL in the BMT subscale of the FACT-BMT, but was also associated with a higher reported symptom load within the L-cGVHD-SC. We hypothesize that an extraverted personality improves coping by communication of bothersome symptoms-a mechanism that has been frequently observed in cancer patients, 15, 34 but also results in higher apparent symptom burden. The reason for the more prominent effect of personality within the American cohort remains unexplained but may be due to a smaller sample size resulting in a greater influence of individual patients. Moreover, both cohorts differed with regard to age and personality distribution and the American cohort included mostly patients with cGVHD while the German-Austrian cohort recruited a significant proportion of patients without cGVHD. Cultural differences and an impact of personality on consent to participation in the trial may also have a role.
The concepts of optimism and pessimism have been extensively studied in cancer patients, with most studies showing a positive effect of optimism on QoL and a more pronounced negative effect of pessimism on QoL and sometimes survival. 13, 33, 35, 36 In contrast, Goetzmann et al. 37 did not detect an effect of Optimism on QoL after organ and BMT. In both cohorts the effect of optimism was limited to a positive impact on emotional well-being captured by the FACT-BMT and reduction of the symptom load as measured by the mental subscale of the L-cGVHD-SC within the American cohort. Pessimism was negatively associated with physical health summary score of the SF-36, an effect which has been already reported in cancer patients. 13, 38, 39 Moreover, within both cohorts pessimism was associated with significantly reduced physical functioning consistent with findings in breast cancer patients, as well as in controls. 40, 41 The negative effect of pessimism on physical functioning was also detectable in the functional well-being subscale of the FACT within both cohorts. Of interest was the relative insensitivity of the SF-36 to personality, which was limited to the effect of pessimism and to a lesser degree to the personality trait conscientiousness within the American cohort, which may be due to focus on functional limitations and interference with daily activities captured by the SF-36 while the FACT's focus on QoL is more vulnerable to the effects of personality. The effect of personality on the reported symptom load of cGVHD as captured by the L-cGVHD-SC was limited to mental and energy symptoms, indicating the relative resistance of symptom self-assessment of cGVHD to the effect of personality. In further support that cGVHD symptoms are less affected by personality, neither physicians' nor patients' severity assessment was related to personality. Of note, optimism affected the patients' self-assessment, explaining in part the divergent assessments of symptom severity between patients and physicians, leading to a too optimistic assessment in patients with profound optimism. The results on the effect of extraversion are important for clinical management insofar that patients with higher levels of extraversion not only provide lower ratings of severity of their cGVHD but also receive a less severe rating from the physician. No conclusion can be drawn from the results on the negative impact of anxiety and depression on severity grading, because depression, in particular, may be due to cGVHD-related impairment, and both are not directly related to personality. 4 In conclusion, the results demonstrate a potential impact of personality on reported QoL and mental symptom load in a longterm follow-up of adult patients after alloHSCT, with a prominent negative effect of neuroticism. A novel observation that requires validation in other cohorts is that pessimism impairs perceived physical health and objective physical functioning. As the effect of personality traits dominates over well-known cofactors such as gender and age, assessment of personality may be considered within randomized trials with QoL or physical functioning as a major end point, so that appropriate adjustments can be made. Moreover, further trials evaluating the impact of personality on patients' self-assessment of changes of QoL in correlation with changes in GVHD severity during treatment are warranted. 
